<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00852046</url>
  </required_header>
  <id_info>
    <org_study_id>#2008.071</org_study_id>
    <nct_id>NCT00852046</nct_id>
  </id_info>
  <brief_title>Adjunct Dexmedetomidine (PrecedexÂ®) Therapy Impact on Sedative and Analgesic Requirement</brief_title>
  <official_title>Adjunct Dexmedetomidine Therapy Impact on Sedative and Analgesic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avera McKennan Hospital &amp; University Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avera McKennan Hospital &amp; University Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess impact of increasing dose of dexmedetomidine on total daily dose of fentanyl and
      propofol while maintaining sedation in a mechanically ventilated patient in a general medical
      intensive care unit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients identified by selection criteria within 48 hours of intubation will be randomly
      assigned to one of three study arms: dexmedetomidine 0.2 mcg/kg/hr, dexmedetomidine 0.6
      mcg/kg/hr, or placebo. If not already on, patients will be converted to propofol and fentanyl
      for sedation and analgesia, which will be titrated to a goal SAS score of 3-4.

      Patients will be monitored, assessed, and evaluated by all regular policies and procedures of
      the institution. Extubation will be at the discretion of the physicians and medical team
      caring for the patient. If the patient is still intubated at five days study drug will then
      be stopped and further use of dexmedetomidine will be at the discretion of the physicians.

      Primary objective will assess impact of increasing dose of dexmedetomidine on total daily
      dose of fentanyl and propofol while maintaining sedation in a mechanically ventilated patient
      in a general medical intensive care unit.

      Secondary objectives include total ventilation time, ICU length of stay, hospital length of
      stay, patient outcomes/mortality, and total pharmacy expenditures.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    PI resigned.
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total daily dose of fentanyl and propofol</measure>
    <time_frame>Daily</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total ventilation time</measure>
    <time_frame>Study ended</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>Study ended.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>Study ended</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient outcomes/mortality</measure>
    <time_frame>Study ended.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total pharmacy expenditures</measure>
    <time_frame>Study ended.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Sedation</condition>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>1. Low dose dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine 0.2 mcg/kg/hr added to fentanyl &amp; propofol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. High dose dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine 0.6 mcg/kg/hr added to fentanyl &amp; propofol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3. Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo added to fentanyl &amp; propofol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>IV solution, 0.2 mcg/kg/hr or 0.6 mcg/kg/hr for a max of 5 days</description>
    <arm_group_label>1. Low dose dexmedetomidine</arm_group_label>
    <arm_group_label>2. High dose dexmedetomidine</arm_group_label>
    <arm_group_label>3. Placebo</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  surgical, medical, or trauma patients requiring sedation for mechanical ventilation

          -  age 18-80

          -  Anticipated ventilation time of &gt; 24 hrs

          -  Reasonable chance of recovery

        Exclusion Criteria:

          -  Severe COPD

          -  Chronic immunosuppression (equivalent to prednisone 7.5 mg daily or higher)

          -  Heart block

          -  Bradycardia

          -  Significant head injury

          -  Goal SAS score of 1-2

          -  Severe hepatic impairment

          -  Hypertriglyceridemia

          -  Allergy to dexmedetomidine, fentanyl, propofol or eggs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John A Kappes, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Avera McKennan Hospital</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2009</study_first_submitted>
  <study_first_submitted_qc>February 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2009</study_first_posted>
  <last_update_submitted>October 5, 2011</last_update_submitted>
  <last_update_submitted_qc>October 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mechanical ventilation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Hypnotics and Sedatives</mesh_term>
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

